Adverum Biotechnologies, Inc.
ADVM
$4.19
$0.020.36%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 1.00M | 1.00M | 1.00M | 1.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 1.00M | 1.00M | 1.00M | 1.00M |
| Cost of Revenue | 91.05M | 91.05M | 71.03M | 57.69M | 48.68M |
| Gross Profit | -91.05M | -90.05M | -70.03M | -56.69M | -47.68M |
| SG&A Expenses | 79.44M | 85.33M | 88.40M | 82.72M | 60.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 208.32M | 195.73M | 178.78M | 159.76M | 128.65M |
| Operating Income | -208.32M | -194.73M | -177.78M | -158.76M | -127.65M |
| Income Before Tax | -204.39M | -189.09M | -170.40M | -150.53M | -119.79M |
| Income Tax Expenses | -- | -- | -- | -- | -1.13M |
| Earnings from Continuing Operations | -204.39 | -189.09 | -170.40 | -150.53 | -118.66 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -204.39M | -189.09M | -170.40M | -150.53M | -118.66M |
| EBIT | -208.32M | -194.73M | -177.78M | -158.76M | -127.65M |
| EBITDA | -205.82M | -191.81M | -174.44M | -155.11M | -123.80M |
| EPS Basic | -9.51 | -9.03 | -8.15 | -7.56 | -7.49 |
| Normalized Basic EPS | -5.95 | -5.65 | -5.10 | -4.72 | -4.75 |
| EPS Diluted | -9.51 | -9.03 | -8.15 | -7.56 | -7.49 |
| Normalized Diluted EPS | -5.95 | -5.65 | -5.10 | -4.72 | -4.75 |
| Average Basic Shares Outstanding | 86.33M | 83.72M | 83.56M | 79.11M | 68.33M |
| Average Diluted Shares Outstanding | 86.33M | 83.72M | 83.56M | 79.11M | 68.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |